KR960021057A - 아크리딘 또는 아크리딘 유도체 보조하의 바이러스의 불활성화 방법 - Google Patents

아크리딘 또는 아크리딘 유도체 보조하의 바이러스의 불활성화 방법 Download PDF

Info

Publication number
KR960021057A
KR960021057A KR1019950047626A KR19950047626A KR960021057A KR 960021057 A KR960021057 A KR 960021057A KR 1019950047626 A KR1019950047626 A KR 1019950047626A KR 19950047626 A KR19950047626 A KR 19950047626A KR 960021057 A KR960021057 A KR 960021057A
Authority
KR
South Korea
Prior art keywords
acridine
methods
virus
concentration
derivatives
Prior art date
Application number
KR1019950047626A
Other languages
English (en)
Other versions
KR100383467B1 (ko
Inventor
베른하르트 디터
Original Assignee
슈타인, 라우페
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 라우페, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 라우페
Publication of KR960021057A publication Critical patent/KR960021057A/ko
Application granted granted Critical
Publication of KR100383467B1 publication Critical patent/KR100383467B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C12N2760/18663—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

본 발명은 외피 또는 비외피 바이러스의 불활성화를 위한, 바람직하게는 벤즈알코늄 클로라이드와 조합된 아크리딘 또는 아크리딘 유도체의 용도에 관한 것이다. 본 발명에 따른 방법은 생물학적 활성이 실질적으로 유지되는 단백질의 존재하에서 수행된다.

Description

아크리딘 또는 아크리딘 유도체 보조하의 바이러스의 불활성화 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 아크리딘 또는 아크리딘 유도체를 사용하는 것을 특징으로하는 바이러스의 불활성화 방법.
  2. 제1항에 있어서, 벤즈알코늄 클로라이드를 부가적으로 사용하는 방법.
  3. 제1항에 있어서, 생물학적 활성이 유지되는 단백질의 존재하에서 수행되는 방법.
  4. 제2항에 있어서, 생물학적 활성이 유지되는 단백질의 존재하에서 수행되는 방법.
  5. 제1항에 있어서, 인큐베이션을 20℃ 내지 160℃온도에서 수행하는 방법.
  6. 제1항에 있어서, 온도가 25 내지 37℃인 방법.
  7. 제1항에 있어서, 인큐베이션을 pH 5 내지 9에서 수행되는 방법.
  8. 제1항에 있어서, 아크리딘 또는 아크리딘 유도체가 0.0001 내지 1.0g/ℓ의 농도로 사용되는 방법.
  9. 제8항에 있어서, 아크리딘 또는 아크리딘 유도체가 0.0005 내지 0.1g/ℓ의 농도로 사용되는 방법.
  10. 제2항에 있어서, 벤즈알코늄 클로라이드가 0.004 내지 0.1g/ℓ의 농도로 사용되는 방법.
  11. 제10항에 있어서, 벤즈알코늄 클로라이드가 0.001 내지 0.05g/ℓ의 농도로 사용되는 방법.
  12. 제1항에 있어서, 인큐베이션 시간이 0.5 내지 10.0시간인 방법.
  13. 제12항에 있어서, 인큐베이션 시간이 2 내지 5시간인 방법.
  14. 제1항에 있어서, 바이러스가 파보바이러스 또는 기타 비외피 바이러스인 방법.
  15. 제1항에 있어서, 바이러스가 외피 바이러스인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950047626A 1994-12-10 1995-12-08 아크리딘또는아크리딘유도체보조하의바이러스의불활성화방법 KR100383467B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4444045.6 1994-12-10
DE4444045A DE4444045C2 (de) 1994-12-10 1994-12-10 Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten

Publications (2)

Publication Number Publication Date
KR960021057A true KR960021057A (ko) 1996-07-18
KR100383467B1 KR100383467B1 (ko) 2003-08-21

Family

ID=6535482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950047626A KR100383467B1 (ko) 1994-12-10 1995-12-08 아크리딘또는아크리딘유도체보조하의바이러스의불활성화방법

Country Status (9)

Country Link
US (1) US6831086B1 (ko)
EP (1) EP0720851A3 (ko)
JP (1) JPH08225455A (ko)
KR (1) KR100383467B1 (ko)
CN (1) CN1163595C (ko)
AU (1) AU693291B2 (ko)
CA (1) CA2164766A1 (ko)
DE (1) DE4444045C2 (ko)
TW (1) TW445296B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
AU744089C (en) * 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation
EP1364944A1 (en) * 1997-01-06 2003-11-26 Cerus Corporation Frangible Compounds for Pathogen Inactivation
US7186543B1 (en) * 1998-07-21 2007-03-06 Gambro Inc. Preparation of vaccines using a photosensitizer and light
DE19834053A1 (de) 1998-07-29 2000-03-30 Centeon Pharma Gmbh Verfahren und Mittel zur Sanatisierung von durch Viren verursachten Kontaminationen
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
JP4794136B2 (ja) * 2004-04-21 2011-10-19 阿蘇製薬株式会社 アクリジン誘導体
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
EP2265117B1 (en) * 2008-04-16 2017-06-07 Howard University Inhibitors of protein phosphatase-1 and uses thereof
CN102481385B (zh) * 2009-06-30 2016-01-27 3M创新有限公司 光活化抗微生物制品及其使用方法
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
KR101710360B1 (ko) 2015-03-17 2017-02-27 서연실 기능성 빗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
JPH01500012A (ja) * 1986-04-07 1989-01-12 アルーシオウフィ，ハビブ 抗病原血液収集装置および方法
GB8809177D0 (en) * 1988-04-19 1988-05-25 Merrell Doe Pharmaceuticals In Method of preventing aids transmission-resulting from blood transfusions
DE3930510A1 (de) * 1989-09-13 1991-03-21 Blutspendedienst Dt Rote Kreuz Verfahren zur inaktivierung von viren in blut und blutprodukten
US5668149A (en) * 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
ZA912842B (en) * 1990-04-16 1992-03-25 Cryopharm Corp Method of inactivation of viral and bacterial blood contaminants
DE4137548A1 (de) * 1991-11-12 1993-05-13 Hepper Martin Antimikrobielle wirkstoffkombination auf der basis von acridinfarbstoffen
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard

Also Published As

Publication number Publication date
JPH08225455A (ja) 1996-09-03
AU4032395A (en) 1996-06-20
KR100383467B1 (ko) 2003-08-21
TW445296B (en) 2001-07-11
CN1163595C (zh) 2004-08-25
DE4444045C2 (de) 1997-04-17
CA2164766A1 (en) 1996-06-11
CN1132249A (zh) 1996-10-02
DE4444045A1 (de) 1996-06-13
EP0720851A2 (de) 1996-07-10
US6831086B1 (en) 2004-12-14
EP0720851A3 (de) 1999-12-22
AU693291B2 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
KR960021057A (ko) 아크리딘 또는 아크리딘 유도체 보조하의 바이러스의 불활성화 방법
ATE57474T1 (de) Ozonentkeimung von blut und blutprodukten.
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
TR200001954T2 (tr) Faktör XA'nın önleyicileri olarak indol türevleri.
EA200100502A1 (ru) СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53
ATE217144T1 (de) Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
ATE244404T1 (de) Zusammensetzungen und verfahren zur hemmung der licht-induzierten inaktivierung von biologischen reagenzien
KR950702640A (ko) 감염증 진단용 프로브
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DE69831406D1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE69902526D1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ES2176263T3 (es) 5,6-dihidropironas derivadas como inhibidores de proteasa y agentes antivirus.
ATE78397T1 (de) Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
ATE253368T1 (de) Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE285255T1 (de) Verfahren zur inaktivierung von viren
ATE145828T1 (de) Verfahren zur desinfektion von muskelskelettgeweben und so aufbereitete gewebe
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
NO994821L (no) Fremgangsmåte ved inaktivering av patogener, spesielt virus, i et biologisk materiale
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee